Drugs / docosapentaenoic acid
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00312455 | Jul 2004 → Jul 2005 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | docosapentaenoic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00312455 ↗ |
| Known as | DPA | “The purpose of this study is to evaluate the effectiveness of the n-3 PUFAs eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) in treating relapse, aggression, and...” NCT00312455 ↗ |
| Modality | Other / unclassified | “n-3 polyunsaturated fatty acids (PUFAs)” NCT00312455 ↗ |